Niacin/simvastatin: Difference between revisions

Browse history interactively

← Previous edit

Content deleted Content added

VisualWikitext

@@ Line 1: / Line 1: @@
+{{Short description|Combination drug}}
 {{Drugbox
+| verifiedrevid = 388938186
 | type              = combo
 | image             = Niacinstr.png
 | image2            = Simvastatin.svg
 | component1        = Niacin
-| class1            = n/a
+| class1            = [[Vitamin]]
 | component2        = Simvastatin
 | class2            = [[Statin]]
-| CAS_number        =
+| CAS_number        = 1054452-10-6
 | ATC_prefix        =
 | ATC_suffix        =
@@ Line 22: / Line 24: @@
 | routes_of_administration = Oral
 }}
-'''Simcor''' ([[Abbott Laboratories|Abbott]]) is a drug combination of the statin drug [[Simvastatin]] and an extended release form of niacin used for the treatment of [[dyslipidemia]]. It was approved by the FDA on February 15, 2008.<ref>{{Cite web|url=http://www.drugs.com/newdrugs/abbott-receives-fda-approval-simcor-niaspan-simvastatin-novel-combination-medicine-comprehensive-846.html |title=Drugs.com, Abbott Receives FDA Approval for Simcor (Niaspan / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management |accessdate=2008-03-15 |work= }}</ref>
+'''Niacin/simvastatin''' (trade name '''Simcor''', by [[Abbott Laboratories|Abbott]]) is a [[combination drug]] consisting of an extended release form of the lipid-lowering drug [[Niacin (substance)|niacin]] and the [[statin]] drug [[simvastatin]].<ref name="pmid20141348">{{cite journal | vauthors = Yiu KH, Cheung BM, Tse HF | title = A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin | journal = Expert Opinion on Investigational Drugs | volume = 19 | issue = 3 | pages = 437–49 | date = March 2010 | pmid = 20141348 | doi = 10.1517/13543781003623223 }}</ref> It is used for the treatment of [[dyslipidemia]]. It was approved by the FDA on February 15, 2008.<ref>{{Cite web|url=https://www.drugs.com/newdrugs/abbott-receives-fda-approval-simcor-niaspan-simvastatin-novel-combination-medicine-comprehensive-846.html |title=Drugs.com, Abbott Receives FDA Approval for Simcor (Niaspan / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management |accessdate=2008-03-15 }}</ref>  On April 15, 2016, the FDA pulled the approval of niacin and fibrates used in combination with statin drugs, citing growing evidence that the benefits of combining niacin or fibrate drugs with statin drugs to not outweigh the risks, compared to statin therapy alone.<ref name=FDAWithdrawal>{{cite web |url=https://www.federalregister.gov/documents/2016/04/18/2016-08894/abbvie-inc-withdrawal-of-approval-of-new-drug-applications-for-advicor-and-simcor |title=AbbVie Inc.; Withdrawal of Approval of New Drug Applications for ADVICOR and SIMCOR |last= |first= |date= 18 April 2016 |website=U.S. Federal Register|access-date=17 May 2020}}</ref> This ruling applied to [[Niacin/lovastatin|Advicor]] in addition to Simcor.<ref name=FDAWithdrawal />
 ==References==
@@ Line 29: / Line 31: @@
 {{Statins}}
+{{DEFAULTSORT:Niacin simvastatin}}
+[[Category:Combination lipid-lowering drugs]]
+[[Category:Drugs developed by AbbVie]]
 {{Cardiovascular-drug-stub}}
-[[Category:Hypolipidemic agents]]
-[[Category:Combination drugs]]